Release date: September 28, 2009
Expiration date: September 28, 2010
Estimated time to complete activity: 1 hour

 

Ira M. Jacobson, MD
Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Medical Director, Center for the Study of Hepatitis C
Weill Cornell Medical College
Attending Physician
New York–Presbyterian Hospital
New York, NY

Mark Sulkowski, MD
Associate Professor of Medicine
Medical Director, Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, MD

 

Mission Suppression: The Implications & Applications of Key Studies in the Management of Chronic Hepatitis B is a newsletter report reviewing the findings of key studies influencing the management of chronic hepatitis B (CHB). This publication will focus on recent studies, outline considerations, and discuss real world applications to clinical practice.


 

Physicians
Physician assistants

After completing this activity, participants will be better able to:
-Identify current CHB treatment goals and outline the primary end points used to measure success
-Discuss significant study results and their implications for the diagnosis and management of CHB
-Summarize new treatment strategies for CHB
-Review new agents used in the treatment of CHB, how they compare with existing agents, and emerging treatment strategies for CHB
-Understand the role of resistance in the long-term management of CHB and design strategies to prevent or manage antiviral resistance


 

Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council
for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Kentucky College of Medicine and HealthmattersCME. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Kentucky College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the publication is provided solely by faculty who have been selected because of recognized expertise in their field.

All faculty members participating in continuing medical education programs sponsored by the University of Kentucky College of Medicine are expected to disclose any real or perceived conflict of interest related to the content of the publication. Faculty disclosures are listed below.

 

Ira M. Jacobson, MD
Contract Research Support: Anadys Pharmaceuticals, Gilead Sciences, GlobeImmune, Human Genome Sciences, Idenix Pharmaceuticals, Intarcia, Novartis, Pharmasset, Roche, Schering-Plough, Valeant Pharmaceuticals International, Vertex Pharmaceuticals
Consultant: Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlobeImmune, Human Genome Sciences, InterMune Pharmaceuticals, Merck, Novartis, Pfizer, Pharmasset, Sanofi-Aventis, Schering-Plough, Tibotec, Vertex Pharmaceuticals, ViroChem Pharma, ZymoGenetics
Speakers’ Bureau: Bristol-Myers Squibb, Gilead Sciences, Novartis, Schering-Plough

Mark Sulkowski, MD
Contract Research Support: Gilead Sciences, Human Genome Sciences, Novartis, Roche Pharmaceuticals, Schering-Plough
Consultant: Bristol-Myers Squibb, Gilead Sciences, Human Genome Sciences/Novartis, Roche Pharmaceuticals, Schering-Plough
Speakers’ Bureau: Gilead Sciences, Novartis

 

This activity is jointly sponsored by the University of Kentucky College of Medicine and HealthmattersCME.




This program is supported by an independent educational grant from Gilead Sciences Medical Affairs.

**Once the "Launch Activity" button is clicked, it may take a minute or more to download.